Nova Scotia-based Immunovaccine (OTCQX:IMMVF) reports positive results from a Phase 1 clinical trial assessing DPX-RSV, its DepoVax prophylactic respiratory syncytial virus (RSV) vaccine candidate, in 40 older adult volunteers.
DPX-RSV was well-tolerated with no serious adverse events reported. The lower dose produced an antigen-specific antibody response in 75% of subjects while the higher dose achieved produced a response in all of the recipients (20 subjects in each cohort).
The company's vaccine delivery approach focuses on targeting the ectodomain (parts of the protein on the surface of the cell or virus) of the SH (small hydrophobic) protein of RSV. According to Immunovaccine, other RSV vaccines target the F and G proteins of the virus which results in some people remaining susceptible to RSV infection. In addition, the immune system is better able to clear RSV infected cells from the respiratory tract via SH-targeted immune responses thereby minimizing the chance of airway obstruction and post-infection complications.
Depo-Vax is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. It produces a specific and sustained immune response, potentially with only a single dose.
Immunovaccine Inc. (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced a preclinical collaboration with The University of Edinburgh's Center for Immunity, Infection and Evolution ("CIIE"). The study will explore if novel CIIE-identified targets, when formulated in the DepoVax™ delivery system, provide immunogenic responses against parasites that cause life-threatening malaria. The collaborators expect to present data later this year.
Malaria is a parasitic disease in which the infection is transferred via bites by Anopheles mosquitoes. The World Malaria Report 2015, released by the World Health Organization, estimated that there were 214 million new cases of malaria worldwide in 2015, resulting in 438,000 deaths.
While there are multiple forms of malaria, this study focuses specifically on the most deadly presentation, in which infected red blood cells stick together, forming clusters within small blood vessels. This process, known as 'rosetting,' can result in hypoxia, organ damage, and can contribute to death.
"Our DepoVax™ platform has a strong track record against a range of deadly infectious diseases, and its sustained delivery system and ability to support multiple antigens make it ideally suited to help address the global health threat posed by malaria as well," said Marianne Stanford, PhD, Director of Research at Immunovaccine. "We are fortunate to work with Professor Alexandra Rowe and her team at CIIE, who have done tremendous work in identifying novel, effective targets across a range of deadly malarial pathogens. With severe malaria being a serious health concern, an effective vaccine that can address the rosetting process has the potential to have a significant positive impact on global malaria mortality rates."
Immunovaccine (OTCQX:IMMVF) and Incyte (INCY -0.5%) enter into a non-exclusive clinical trial collaboration to evaluate the combination of Immunovaccine's DPX-Survivac, Incyte's epacadostat and cyclophosphamide in platinum-resistant ovarian cancer patients who are at high risk of recurrence. The Phase 1b study will enroll ~20 subjects. Financial terms are not disclosed.
DPX-Survivac is a therapeutic vaccine candidate that contains survivin-based peptide antigens formulated in its DepoVax adjuvanting platform. It is designed to train the immune system to generate robust CD8 T cells against survivin, a protein expressed in most cancer cells that inhibits apoptosis (programmed cell death).
Epacadostat is a small molecule inhibitor of IDO1, an immunosuppressive enzyme that has been shown to induce regulatory T cell generation and activation thereby allowing cancer cells to avoid detection by the immune system.